ASCO 2026 | The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
Alexandra Haugh
• 30 May 2026
Alexandra Haugh, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses the rationale and design of a Phase I/II trial (NCT07288112) evaluating DOC1021, a personalized dendritic cell vaccine for refractory melanoma. Dr Haugh explains how tumor-derived antigens are loaded onto dendritic cells and injected into draining lymph nodes to stimulate an anti-tumor immune response. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
